P ulmonary arterial hypertension (PAH), manifested by a maladaptive elevation in pulmonary arterial pressure, is a progressive lung vascular disorder that causes occlusion of the pulmonary vascular lumen, increased pulmonary vascular resistance, right-sided heart failure, and eventual death. 1, 2 Because of deficiencies in the present knowledge of PAH pathogenesis, effective therapies are limited and the mortality rate in the patient population is still high. [3] [4] [5] Hence, there is a need for a better understanding of the molecular pathogenesis of this disease.
Pulmonary arterial remodeling is an important pathologic hallmark of PAH, 6, 7 and excessive proliferation and migration of pulmonary artery smooth muscle cells (PASMCs) is thought to be a major cause of the vascular remodeling. 8, 9 Plateletderived growth factor (PDGF), a potent mitogen of PASMCs, 2, 10, 11 with PDGFBB being the key homodimer isoform, plays a critical role in vascular remodeling. 12, 13 It is known that, in the pulmonary artery, PDGFBB is synthesized by both endothelial cells and fibroblasts and it can act in a paracrine manner on PASMCs in the medial layer of the vessel wall. It induces PASMCs to switch from a contractile phenotype to a proliferative and migratory phenotype, which then leads to medial vessel wall remodeling. [14] [15] [16] It is also known that in settings of experimental PAH, expression of PDGFBB and phosphorylation of PDGF receptor are increased in lungs with PAH and lung vascular cells 2, 17, 18 ; the administration of the PDGF receptor inhibitor, imatinib mesylate, has been shown to significantly reverse pulmonary vascular remodeling in animal models of PAH. 19, 20 Consistent with these findings, high levels of PDGFBB in lung tissues of patients with PAH have correlated with the severity of PAH. 21, 22 Hence, the role of PDGF in PAH pathogenesis deserves greater attention, and this study elucidating the downstream regulatory mechanisms of PDGF is highly relevant. MicroRNAs (miRNAs) are noncoding RNAs of %19 to 25 nucleotides that negatively regulate gene expression at the posttranscriptional and/or translational level. 23 Downregulation of specific miRNAs is a common feature of proliferative diseases, such as cancer, and identification of miRNA targets with critical functions supports the role of corresponding miRNAs as tumor suppressors. [24] [25] [26] At this interface, miRNAs are emerging as a class of therapeutic agents that can control disease in a propathogenic or antipathogenic manner. 27 Recently, using miRNA profiling techniques, many miRNAs have been identified to have altered expression in patients with PAH [28] [29] [30] and in PAH animal models, [31] [32] [33] [34] but the great variation in these screening results requires cautious analysis of the function and mechanisms involved of each identified miRNA candidate. To date, the roles of a few miRNAs in mediating differentiation, migration, and/or proliferation of PASMCs have been reported 28, [35] [36] [37] [38] ; however, more complex studies are required to explore the potential pathogenic or therapeutic roles of PAH-dysregulated miRNAs.
In a recent study, we focused on the identification of PDGFBB-regulated miRNAs and their functions related to PASMC proliferation and migration. By profiling miRNA expression in PDGFBB-stimulated human PASMCs, we found 15 miRNAs that were significantly dysregulated, among which miR-1281 was 1 of the 3 most downregulated miRNAs. 39 miR-1281 is a relatively less conserved miRNA annotated only in 3 placental mammals (ie, humans, chimpanzees, and cattle; http://www.ncbi.nlm.nih.gov/gene/?term=miR-1281) and is only associated with a few diseases as a putative biomarker. [40] [41] [42] In this study, we found that the position and sequence of miR-1281 are conserved between humans and rodents and, therefore, took advantage of this to closely investigate the function and regulatory mechanism of miR-1281 action in rat PASMCs. As a result, the epigenetic regulators DNA methyltransferase 1 (DNMT1) and histone deacetylase 4 (HDAC4) were identified as agents that form a regulatory axis with miR-1281 (ie, phosphatidylinositol 3-kinase [PI3K]-DNMT1-miR-1281-HDAC4) and that function downstream of PDGFBB to control PASMC proliferation and migration.
Methods
The data, analytic methods, and study materials will be available, on request, from Shenzhen University (Shenzhen, China).
Clinical Perspective
What Is New?
• Platelet-derived growth factor BB-induced repression of miR-1281 is a conserved phenomenon in human and rat pulmonary artery smooth muscle cells.
• miR-1281 inhibits pulmonary artery smooth muscle cell proliferation and migration, at least in part through targeting histone deacetylase 4.
• Phosphatidylinositol 3-kinase-DNA methyltransferase 1-miR-1281-histone deacetylase 4 is an integrated regulatory axis mediating platelet-derived growth factor BB function.
• Expression of miR-1281 is consistently reduced in hypoxic pulmonary artery smooth muscle cells, rats with monocrotaline-induced pulmonary arterial hypertension, and patients with coronary heart disease-pulmonary arterial hypertension.
What Are the Clinical Implications?
• Inhibiting the activity of platelet-derived growth factor receptor is an effective approach reversing pulmonary arterial hypertension-related pulmonary artery smooth muscle cell proliferation and vascular remodeling; identifying the molecular agents mediating platelet-derived growth factor function is critical for seeking novel therapeutic targets.
• DNA methyltransferases, microRNA, and histone deacetylases are important epigenetic agents regulating the pulmonary arterial hypertension-proliferative phenotype; their interactions and integrated biological roles are barely understood.
Monocrotaline-Induced PAH Model in Rats
Sprague-Dawley rats were obtained from the Medical and Experimental Animal Center of Gongdong Province (China). Adult male rats (weight, 250-300 g; age, 10-12 weeks) were used for experiments. All animal procedures conformed to the Guide for Care and Use of Laboratory Animals, published by the US National Institutes of Health (8th edition, 2011), and were approved by the Animal Care and Use Committee of Shenzhen University. PAH was induced in Sprague-Dawley rats (10 per experimental group) by a single IP injection with monocrotaline (60 mg/kg; Sigma-Aldrich, St Louis, MO). Pulmonary arteries collected from rats with confirmed monocrotalineinduced PAH and healthy control rats were used for experiments ( Figure S12 ).
Human Subjects
Serum samples were collected from healthy infants and infants with coronary heart disease-PAH (including ventricular septal defect or atrial septal defect) at Fuwai Hospital (Beijing, China; refer to Table S1 for detailed participant information). The blood samples were centrifuged at 3000g for 10 minutes at 4°C and stored at À80°C until use. This study was approved by the ethics committee of Fuwai Hospital, with the requirement for informed consent waived.
Cell Culture Experiments
Human embryonic kidney 293T and 293A cells were obtained from American Type Culture Collection (Manassas, VA) and cultured in DMEM supplemented with 10% fetal bovine serum. Human pulmonary arterial smooth muscle cells (PASMCs) were purchased from Sciencell, San Diego, CA and cultured in smooth muscle cell medium, as previously described. 43 Rat
PASMCs were isolated and cultured in DMEM supplemented with 10% fetal bovine serum, as previously described. 34 The purity of rat PASMCs was checked by immunofluorescence staining with a-smooth muscle actin (Sigma-Aldrich, Burlington, MA 
Cell Proliferation and Migration Assays
Cell proliferation was assessed by 5-Ethynyl-2 0 -deoxyuridine (EdU) incorporation. 5-Ethynyl-2 0 -deoxyuridine labeling was performed using an EdU Assay Kit (Ribobio), according to manufacturer's instruction. The stained cells were examined using a fluorescent-inverted microscope (Nikon, Tokyo, Japan). Cell proliferation rate was calculated as the number of EdU-stained cells/the number of 4 0 ,6-diamidino-2-phenylindole-stained cells. Cell migration was determined by the wound-healing assay, as reported previously. 44 In brief, cells were maintained in starvation condition for 12 hours, then a line scratch was made in the cell layer and photographed immediately as initial image (0 hour 
Luciferase Assay
Approximately 1910 4 293A cells were seeded in quadruplicate in 48-well plates, and they were cotransfected with dualluciferase reporter plasmids together with either miR-1281 or control mimics. The cells were lysed for luciferase activity measurement using a Lumat LB9508 luminometer (Berthold, Wildbad, Germany) after 48 hours of transfection. The firefly luciferase activity expressed in the same vector was used as an internal control for normalization.
DNA Methylation Assay
Genomic DNA was isolated from rat PASMCs treated with PDGFBB or dimethyl sulfoxide for 72 hours. Approximately 1 lg of DNA from each sample was bisulfite converted and cleaned up using EpiTect Bisulfite kit (Qiagen, Hilden, Germany), following the manufacturer's instruction. Nested PCR was used to amplify the CpG island from bisulfite-treated DNA samples (primer sequences are summarized in Table S2) , with the PCR setup described by Wang et al. 47 The PCR product was gel purified and sequenced directly with BigDye 3.1 using primer CpG-F2. For cytosine methylation analysis, a simple method verified and recommended by Finn et al 48 
Statistical Analysis
Statistical analyses were performed using the SPSS version 13.0 software 261 package (SPSS) for Windows. All data are presented as mean valuesAESD of 3 experiments (for proliferation and migration assays, data were extracted from 5 and 6 batches of experiments, respectively). When only 2 groups were compared, the statistical differences were evaluated with the double-sided Student t test. Significant differences between groups were analyzed by 1-way ANOVA, taking P<0.05 as a significant difference.
Results miR-1281 Is Downregulated by PDGFBB in PASMCs
Previously, we identified that miR-1281 is downregulated by PDGFBB treatment in human PASMCs. 39 According to the National Center for Biotechnology Information database (http://www.ncbi.nlm.nih.gov/gene/100302237), miR-1281 originates from the upstream region of EP300 5 0 -UTR in the human genome (EP300: E1A binding protein p300, a lysine acetyltransferase). Through a sequence alignment (Figure 1A) , the location and sequence of the MIR-1281 gene were highly conserved among human, rat, and mouse genomes, with them differing only at 1 nucleotide outside the mature miR-1281 sequence. Hence, all experiments have been done with rat PASMCs. The repressing effect of PDGFBB on miR-1281 in PASMCs was revalidated in both human and rat PASMCs (downregulated by %60%; Figure 1B ). Further sets of qRT-PCR revealed that the expression level of miR-1281 was inversely correlated with time (within 12 hours; Figure 1C ) and concentration (<100 ng/mL; Figure 1D ) of PDGFBB treatment. When other growth factors (ie, VEGF, endothelin 1, b-fibroblast growth factor, transforming growth factor-b, angiotensin 2, insulin-like growth factor-1, PDGFAA, and PDGFBB) were applied to PASMCs, most of them did not significantly alter miR-1281 expression; however, PDGF (especially PDGFBB) significantly repressed miR-1281 expression ( Figure 1E ), indicating a major role for miR-1281 in PASMCs, acting downstream of PDGF.
Expression of miR-1281 Suppresses the Proliferative and Migratory Phenotype of PASMCs
To examine if miR-1281 modulates PASMC phenotype, miR-1281 mimic was transfected into PASMCs, which led to an increase of miR-1281 steady-state level by almost 200-fold ( Figure 2A ). Using an EdU incorporation assay, the miR-1281 mimic repressed PASMC proliferation by %30%, with or without added PDGFBB ( Figure 2B ), indicating that miR-1281 can directly suppress PASMC proliferation and attenuate PDGFBB-stimulated proliferation. To confirm these data, miR-1281 inhibitor was used to inhibit endogenous miR-1281, which decreased the steady-state level of miR-1281 by 75% ( Figure 2C ); this was greater than the maximum extent of repression achieved by treatment with PDGFBB ( Figure 1D ). Transfection of miR-1281 inhibitor significantly increased PASMC proliferation ( Figure 2D ), supporting the role of miR-1281 as an inhibitor of PASMC proliferation.
Next, the wound-healing assay was performed to assess the effect of miR-1281 on cell migration. Transfection of miR-1281 mimic significantly suppressed PASMC migration both with and without PDGFBB treatments ( Figure 2E ). Complementing these findings are the results with an miR-1281 inhibitor, in which the inhibition of miR-1281 promoted PASMC migration ( Figure 2F ). Taken together, these data indicate that miR-1281 represses PASMC proliferation and migration and that this is one mechanism by which PDGFBB induces PASMC proliferation and migration and vessel wall remodeling.
To see if miR-1281 influences other PASMC phenotypes, we analyzed the expression of cell contractile marker proteins (ie, Smoothelin, a-smooth muscle actin, and SM-22a) via Western blotting; we did not find a significant change in miR-1281 mimic-transfected PASMCs in comparison with control mimic-transfected PASMCs ( Figure S1 ). This suggests that miR-1281 has no influence on the contractile phenotype of PASMCs.
miR-1281 Targets HDAC4 in PASMCs
According to the targetscan webserver (release 6.2; http:// www.targetscan.org/cgi-bin/targetscan/vert_61/targetsca n.cgi?species=Human&gid=&mir_sc=&mir_c=&mir_nc=miR-1281&mirg=), 12 transcript targets were predicted to carry conserved binding sites for miR-1281, where 3 are annotated to play roles in diverse cellular processes, including cell proliferation and migration (namely HDAC4, 49 PTPRD, 50 and WNT3A). 51 Hence, we determined if HDAC4, PTPRD, and WNT3A are directly targeted by miR-1281. First, each 3 0 -UTR fragment of these genes carrying miR-1281 binding site ( Figure 3A ) was cloned into a luciferase reporter plasmid, and 3 0 -UTR luciferase assays were conducted. As shown in Figure 3B , compared with control mimic, cotransfection of miR-1281 mimic with either PTPRD-3 0 -UTR or HDAC4-3 0 -UTR reporter plasmids displayed significantly reduced luciferase activity, which was not observed for the cotransfection event of miR-1281 mimic and WNT3A-3 0 -UTR plasmids. This suggests that only HDAC4 and PTPRD are direct targets of miR-1281, but WNT3A is not. Supporting this, it was demonstrated that the miR-1281-induced repression could be abolished by mutating the miR-1281 binding sites in HDAC4 3 0 -UTR and PTPRD 3 0 -UTR ( Figure 3C and Figure S2A ), suggesting that 3 0 -UTR fragments of these 2 genes contain functional binding sites of miR-1281 seed region. Next, to check if expression of HDAC4 and PTPRD are regulated by miR-1281 in PDGFBB-stimulated PASMCs, the mRNA and/or protein levels of HDAC4 and PTPRD in response to PDGFBB were analyzed. As shown in Figure S2B , mRNA level of PTPRD was reduced in response to PDGFBB, which disagreed with an expectation of target deregulation DOI: 10.1161/JAHA.117.007572
Journal of the American Heart Association caused by PDGFBB-repressed miR-1281. This finding indicates that in PASMCs, PTPRD may not be regulated primarily by miR-1281, but some other PDGF-related regulatory mechanism may be involved. In contrast, mRNA level of HDAC4 stayed unchanged, whereas the protein level increased significantly ( Figure 3D and 3E), which is consistent with the PDGFBB-induced repression of miR-1281. Further verification was performed by transfecting miR-1281 mimic into PASMCs, and the reduction of HDAC4 protein level was observed both with and without PDGFBB treatment (Figure 3F) . Therefore, these data demonstrate that, in PASMCs, miR-1281 regulates HDAC4 expression at the translational level; they also show that PDGFBB-induced suppression of miR-1281 would result in deregulated expression of HDAC4 protein.
Cellular Function of HDAC4 Inversely Correlates With Expression of miR-1281
We investigated if HDAC4 mediates the effects of miR-1281. To address this, shHDAC4 was constructed and transducted into PASMCs via lentiviral infection, which achieved %80% inhibition of HDAC4 protein level ( Figure S3A ). An EdU incorporation assay showed that shHDAC4 infection suppressed PASMC proliferation either with or without PDGFBB treatment ( Figure S3B) ; a wound-healing assay proved that shHDAC4 infection also suppressed PASMC migration (Figure S3C) . On the basis of these observations, we can infer that expression of HDAC4 promotes proliferation and migration of PASMCs and contributes to PDGFBB-induced cell dysfunction, which is inversely correlated with the cellular function of miR-1281.
miR-1281/HDAC4 Module Acts by Influencing Activities of Related Transcription Factors
To determine the mode of action of HDAC4, 2 possible regulatory pathways of miR-1281/HDAC4 pathway were analyzed. First, by transfecting mimic miR-1281 into PASMCs, we tested if the expression of miR-1281 influenced the histone acetylation status of PASMCs. However, we found that Journal of the American Heart Association overexpression of miR-1281 failed to significantly enhance the acetylation status of histone H3, H4, H2A, or H2B ( Figure S4) ; therefore, we do not expect miR-1281 to exert its cellular effects by influencing the PASMC transcriptome globally. Second, because HDAC4 can act as a transcriptional coregulator that may interact with myocyte enhancer factor 2, 52 activating transcription factor 4, 53 transforming growth factor-b, 54 and hypoxia-inducible factor (HIF)-1a 55, 56 in PASMCs, we investigated if miR-1281/HDAC4 pathway influenced the transcription of corresponding downstream genes kruppel-like factor 2 (KLF2), KLF4, CCAAT/enhancer-binding protein-homologous protein (CHOP), tribbles homolog 3 (TRB3), drosophila mothers against decapentaplegic protein 3 (SMAD3), vascular endothelial growth factor (VEGF), and glucose transporter-1 (GLUT-1). Our results demonstrate that inhibition of HDAC4 by siHDAC4 led to decreased mRNA levels of CHOP, SMAD3, VEGF, and GLUT-1, but increased mRNA level of TRB3 ( Figure 4A) ; agreeing with this, overexpression of miR-1281 by miR-1281 mimic also led to decreased mRNA levels of SMAD3, VEGF, and GLUT-1 ( Figure 4B ). Hence, it appears that genes functioning downstream of HDAC4 can be, in part, regulated by miR-1281. Notably, miR-1281 overexpression also induced downregulation of KLF2 and TRB3. This is supported by miR-1281 inhibitor-induced upregulation of these 2 genes (Figure 4C ), reminding us of the difference between miR-1281 and HDAC4 downstream regulatory networks.
EGR1 Regulation of EP300 Is Not the Key Mechanism Leading to Repression of miR-1281 by PDGFBB
Next, the regulatory mechanism underlying PDGFBB repression of miR-1281 was investigated. As mentioned, MIR-1281 originates from an upstream region of EP300 5 0 end, and the latter carries 6 EGR1 binding sites and can respond to EGR1 activation. 57 In rat EP300 5 0 end, 6 EGR1 binding sites were identified to scatter around the MIR-1281 flanking region ( Figure S5A) ; hence, the effect of EGR1 on miR-1281 expression was analyzed. First, in PDGFBB-treated PASMCs, the mRNA levels of EGR1 increased by >4-fold within 4 hours of PDGFBB treatment, and then decreased gradually and returned to the original level after 12 hours ( Figure S5B ). This revealed an earlier response of EGR1 than that of miR-1281 (at 12 hours; Figure 1C ) to PDGFBB treatment. Accordingly, an siRNA against EGR1 was transfected into PASMCs, which knocked down the mRNA expression of EGR1 by 70% ( Figure S5C ). Under normal culture conditions, transfection of an siRNA against EGR1 induced the expression of miR-1281 by >60% in PASMCs ( Figure S5D) ; however, under PDGFBB treatment, the siRNA against EGR1 failed to significantly alter miR-1281 expression (at 12 hours; Figure S5E ), suggesting the possibility that other regulatory mechanism(s) exist to mediate the repressing effect of PDGFBB on miR-1281 expression. 
PI3K-Induced DNMT1 Expression Results in Repression of miR-1281
Via promoter prediction webserver (FirstEF, http://rulai.cshl. org/tools/FirstEF), we identified a CpG island located in the vicinity of 5 0 upstream region of MIR-1281 and EP300
( Figure S6A) . By sequence alignment, we found that this CpG island is highly conserved between human and rat genomes ( Figure S6B ). Then, using DNA samples isolated from rat PASMCs treated with either PDGFBB or dimethyl sulfoxide (control), the methylation status of CG dinucleotide sites within this CpG island was analyzed, and we found that PDGFBB treatment enhanced methylation status of most cytosine residues in these CG dinucleotides ( Figure S6D) . Moreover, addition of DNMT inhibitor (ie, 5-aza-2 0 -deoxycytidine) reversed the PDGFBB-induced repression of miR-1281, from <40% to %80% ( Figure S6E ). Hence, these data emphasize the importance of PDGFBB-induced CpG island methylation on miR-1281 expression, and the member (s) of DNMT is(are) assumed to act as the important repressor (s). Previously, PDGFBB treatment was induced significant upregulation of DNMT1, but not DNMT3A or DNMT3B 39 ;
therefore, DNMT1 is assumed to be the DNMT responsible for repressed miR-1281 expression. Herein, we found that the protein level of DNMT1 correlated with PDGFBB treatment in a dose-dependent manner ( Figure 5A ), which is in line with the PDGFBB dose-dependent repression of miR-1281 (Figure 1D) . Then, we demonstrated that silencing DNMT1 expression by transfecting si-DNMT1 in PASMCs partially recovers PDGFBB-induced miR-1281 repression ( Figure 5B and 5C). Thus, these data strongly support the notion that increased expression of DNMT1 underlies PDGFBB-induced repression of miR-1281.
To investigate which PDGFBB-activated pathway(s) upregulate(s) DNMT1 in PASMCs, we used specific inhibitors (SCH772948, SP600125, enzastaurin, pictilisib, and saracatinib) to block PDGF-related signaling pathways (extracellular signal-regulated kinase [ERK] 1/2, c-Jun N-terminal Kinase, protein kinase Cb, PI3K, and sarcoma (Src), respectively) in PDGFBB-treated PASMCs. The inhibitor of PDGF receptor (ie, imatinib) was used as a positive control to illustrate complete inhibition of PDGFBB effect on DNMT1. As shown in Figure 5D , pretreatment with either imatinib (positive control) or pictilisib fully inhibited PDGFBB-induced increase in DNMT1 mRNA, suggesting that the upregulation of DNMT1 was attributable to activation of the PI3K pathway by PDGF receptor. After this, different concentrations of pictilisib were applied to PASMCs, which were then treated with PDGFBB. The qRT-PCR analysis showed that pictilisib attenuates the effect of PDGFBB on DNMT1 mRNA expression at 0.02 to 1 lmol/L, but it did not induce any further reduction in DNMT1 mRNA levels when higher concentrations of pictilisib were applied ( Figure 5E ). Finally, miR-1281 level was also measured in the previously described RNA samples. As expected, pretreatment with pictilisib attenuated PDGFBB repression of miR-1281 level ( Figure 5F ). Overall, the data indicate that PDGFBB-activated PI3K pathway leads to upregulation of DNMT1, which, in turn, acts as the repressor of miR-1281 expression. Besides, the inhibitor of ERK1/2 (ie, SCH772984) also attenuated the inhibitory effect of PDGFBB on miR-1281 expression ( Figure 5F ), but it did not influence the mRNA level of DNMT1 ( Figure 5D ); these findings indicated that the expression of miR-1281 can be controlled by another PDGF-related pathway, and this would be independent of DNMT1 regulation.
Reduced miR-1281 Levels Were Found in Hypoxic PASMCs in Vitro, in Pulmonary Arteries of Rats With Monocrotaline-Induced PAH, and in Serum of Patients With Coronary Heart Disease-PAH
To correlate downregulated miR-1281 levels with the presence of PAH, we compared miR-1281 level between hypoxic and normoxic PASMCs in vitro, because hypoxia does induce pulmonary arterial remodeling and PAH. 58 The results revealed a significant downregulation of miR-1281 in PASMCs after 12 and 24 hours of hypoxia ( Figure 6A ). Then, we measured miR-1281 level in pulmonary arteries isolated from rats with monocrotaline-induced PAH and found that miR-1281 levels were significantly decreased compared with those of control rats ( Figure 6B ). Finally, we measured miR-1281 level in serum samples collected individually from 13 healthy donors and 29 patients with coronary heart disease-PAH (refer to Table S1 for participant information). The miR-1281 level was significantly lower in serum of patients with PAH compared with healthy donors ( Figure 6C ). In summary, these data consistently suggest a close relationship between miR-1281 and PAH, and they suggest that a reduction in the level of miR-1281 could be a potential biomarker of PAH.
Discussion
Mature quiescent PASMCs retain a significant capacity to become proproliferative, promigratory, and antiapoptotic in response to a multitude of stimuli, 16, 59, 60 and previous studies protein expression in PAH-PASMCs and distal pulmonary arteries and demonstrated that inhibition of HDAC6 not only rescues PASMC proliferation and antiapoptotic phenotype, but also reverses PAH symptoms in monocrotaline rat model. Usui et al 62 found that HDAC4 mediates the development of hypertension in spontaneously hypertensive rats, by controlling proliferation and migration of vascular SMCs. Hence, revealing the mechanism regulating each HDAC expression would be important for selective inhibition of HDAC members and evaluating their individual therapeutic potential. In this study, we used PDGFBB treatment as the trigger for PASMC proliferation and migration and found that significant downregulation of miR-1281, coupled with a significant upregulation of HDAC4 ( Figures 1B and 3E) (the latter being a direct target of miR-1281) ( Figure 3B and 3C ). miR-1281 inhibits PASMC proliferation and migration (Figure 2) , whereas HDAC4 has an opposite effect ( Figure S3 ). These data indicate that the miR-1281/HDAC4 complex and signaling pathway regulates PASMC function and that HDAC4 is downstream from miR-1281. Because the cellular effects of this miRNA pathway were evident both with and without PDGFBB treatment, it is reasonable to assume that the miR-1281/HDAC4 module would also come into play if the expression of miR-1281 was downregulated by other stimuli. Supporting this, we found reduced miR-1281 levels in hypoxia-treated PASMCs and pulmonary arteries isolated from monocrotaline-treated rats ( Figure 6A and 6B ). Therefore, further investigation may be needed to analyze the broader biological role of the miR-1281/HDAC4 pathway. Further experimentation would help clarify the findings of Zhao et al, who identified the increased expression of HDAC1/4/5 in lungs from human idiopathic PAH, but only focused on the role of HDAC1/5 in remodeled pulmonary vessels. 63 Nozik-Grayck and colleagues found that HDAC3
induced the suppression of superoxide dismutase (ie, superoxide dismutase 3) in PASMCs and suggested that the HDAC pan-inhibitor Trichostatin A (TSA) may protect against idiopathic PAH, in part, by blocking HDAC3 activity and increasing PASMC superoxide dismutase 3 expression. 64 To elucidate the regulatory mechanisms of the miR-1281/ HDAC4 pathway, 2 possible actions of HDAC4 were considered: it may be globally influencing the PASMC transcriptome by altering the acetylation status of histone(s), or it may be specifically interacting with related commanding transcription factors. The data from our study support the latter case. Namely, overexpression of miR-1281 did not significantly influence the acetylation status of any PASMC histone ( Figure S4 ), but only altered the transcription of specific transcription factors that may also function downstream of HDAC4 (eg, VEGF and GLUT-1; Figure 4) . The reduced mRNA level of VEGF and GLUT-1 in si-HDAC4-or miR-1281 mimictransfected PASMCs indicates a reduced transcriptional activity of HIF-1a, which is in line with the reduced mRNA level of HIF-1a identified in si-HDAC4-and miR-1281 mimictransfected PASMCs ( Figure S7 ). Hence, it is hypothesized that the miR-1281/HDAC4 pathway could change the HIF-1a expression and transcriptional activity. More interestingly, the association of VEGF and HIF-1a with PAH development 65 may indicate that they participated in the functional regulatory network downstream of miR-1281/HDAC4. However, the increased TRB3 mRNA level identified in both miR-1281 mimic-treated and si-HDAC4-transfected cells illustrates the difference between HDAC4 and miR-1281 regulation of PASMCs ( Figure 4A and 4B), which is reasonable considering that miRNAs usually serve as fine tuners of target genes and exert their influence by targeting several genes. Hence, to fully understand the regulatory network and elucidate the difference between HDAC4 and miR-1281 regulation of PASMCs, relative RNA-sequencing studies may be required. Recently, altered miR-1281 level has been identified in some diseases: it is upregulated in serum samples of patients with abdominal aortic aneurysm 40 and in patients with malignant pleural mesothelioma, 41 whereas it is downregulated in plasma samples of patients with immune thrombocytopenic purpura. 42 Hence, miR-1281 has been known for its potential to be a biomarker in a few disease diagnoses, but no reported data have associated miR-1281 with any specific cellular function. This study connected miR-1281 with PAH by revealing a downregulated miR-1281 level in serum of patients with coronary heart disease-PAH; moreover, this study provides the first evidence for miR-1281 to act as a downstream mediator of PDGF effects in PASMCs. We found that not only the sequence and location of MIR-1281 gene were conserved between human and murine genomes ( Figure 1A ), but also the downregulation of miR-1281 is a conserved phenomenon between PDGFBB-treated human and rat PASMCs ( Figure 1B ; data obtained from human PASMCs are not shown). The expression of rat PASMC miR-1281 is regulated by PDGFBB treatment in a dose-and time-dependent manner ( Figure 1C and 1D), indicating the tight correlation between PASMC miR-1281 levels and the effect of PDGFBB. Of the many growth factors that were tested (ie, VEGF, endothelin 1, b-fibroblast growth factor, transforming growth factor-b, angiotensin 2, and insulin-like growth factor-1), because PDGFBB induced the greatest decrease in miR-1281 level in PASMCs ( Figure 1E ) and this appeared to be a specific phenomenon in PASMCs ( Figure S8 ), we suggest that miR-1281 may be a good indicator of PDGFBB effect on PASMCs, which could be used as a reference miRNA in related studies in the future. The annotated location of MIR-1281 gene flanks the 5 0 ends of EP300 first exon, where we identified 6 EGR1 binding sites scattered around. Because EGR1 has been reported to activate or repress EP300 promoter, depending on the stimulus, 57 the identified PDGFBB upregulation of EGR1 ( Figure S5B ) is supposed to influence the transcription of miR-1281. However, our experiment did not support this because inhibition of EGR1 by an siRNA against EGR1 did not affect PDGFBB-induced repression of miR-1281 ( Figure S5E ). Instead, PDGFBB induced a dose-dependent upregulation of DNMT1 activity, and the inhibition of DNMT1 activity by either DNMT pan-inhibitor 5-aza-2 0 -deoxycytidine or si-DNMT1 was found to greatly recover PDGFBB repression of miR-1281 ( Figure S6E and Figure 5C ). This indicates that DNMT1 is a major inhibitor of miR-1281 in PDGFBB-treated PASMCs, and it may surpass the effects of EGR1 regulation of miR-1281 by maintaining a hypermethylation state of the CpG islands around miR-1281 promoter. On the basis of these findings, we hypothesize a scenario in which in normal PASMCs, the methylation status of miR-1281 5 0 upstream is low, such that EGR1 can bind to the miR-1281 72 In conclusion, we propose that the regulatory axis of PI3K-DNMT1-miR-1281-HDAC4 is a novel PDGFBB-responsive pathway that plays an important role in PASMC proliferation and migration ( Figure 6D ). The hierarchical relationship between DNMT1 and HDAC4 may provide a new explanation for a recent report that lung DNA dysmethylation underlies pulmonary vascular dysfunction in the offspring of pregnant mice with a restrictive diet, whereas administration of TSA to offspring of pregnant mice with a restrictive diet normalized their vascular function. 76 Overall, our data point to a promising role for miR-1281 as a therapeutic target in the treatment of pulmonary hypertension. miR-328 is another functional miRNA being identified that is downregulated in PDGFBB-treated PASMCs. 39 We transfected miR-1281 inhibitor and miR-328 inhibitor individually or together into PASMCs, and found no influence of miR-1281 inhibition on miR-328 expression and vice versa (Figures S10 and S11 ). Functional assays demonstrated that simultaneous inhibition of both miR-1281 and miR-328 did not produce greater effect on PASMC proliferation or migration than individual inhibition. Hence, it is suggested that PDGFBB can be downregulated by both miR-1281 and miR-328; they function independently to ensure an accelerated cell proliferation and migration outcome. Western blot assay of acetylated Histone H3 A), H4 B), H2A C) and H2B D) were performed by examining respective acetylation sites (i.e. lysine residues as specified in each representative blotting figure, left panels). Corresponding total Histone was used as loading control. Statistic analysis found no significant difference of the acetylation status in miR-1281 mimic-or control mimictransfected PASMCs. N.S. indicates no significant difference (right panels). MiR-1281 inhibitor and miR-328 inhibitor were transfected individually or together into PASMCs for 48h. qRT-PCR analysis in RNA samples extracted from these PASMCs demonstrated that inhibition of miR-1281 would not influence the expression of miR-328 A), and vice versa B). Proliferation assay C) and migration assay D) performed on these cells demonstrated that simultaneous inhibition of both miR-1281 and miR-328 did not produce greater effect on PASMC proliferation or migration than individual inhibition. Each result presents the statistic analysis based on four independent batches of experiments.
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